Floatz logo

ct-0508

Carcinoma, Transitional Cell

Carisma Therapeutics IncCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Carcinoma, Transitional Cell cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Astellas Pharma Global Development, Inc.
Phase 2BB
MITOMYCIN C
UroGen Pharma Ltd.
Phase 3B
Pembrolizumab
Carisma Therapeutics Inc
Phase 1/2B
Vinflunine
Bristol-Myers Squibb
Phase 2B
Carboplatin
Astellas Pharma Global Development, Inc.
Phase 1/2B

View all 20 →

Same molecule, other indications

ct-0508 is also rated in:

adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
bile duct cancerDormant
CC
Indicative ·
43 / 100
View asset →
HER2 positive breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →